The Trump administration's coronavirus vaccine effort is coming under new scrutiny after failing to lock in a chance to buy millions of additional doses of Pfizer’s vaccine
The go-ahead Wednesday for the vaccine from American drugmaker Pfizer and Germany’s BioNTech comes as the virus surges again in the United States and Europe.